Neratinib treatment for HER2+ early breast cancer in China
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is looking at how neratinib is used as extended treatment after early-stage HER2+ breast cancer, and how it affects patient outcomes in real-world care. You might qualify if you’re an adult with HER2+ early breast cancer that doctors consider free of recurrence and metastasis, and you’re able to take neratinib as prescribed in China.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older and can give informed consent (with ethics approval).
- Your breast cancer is HER2-positive (HER2 overexpressed/amplified) and is early-stage.
- Doctors think your cancer has no signs of return (recurrence) and has not spread to other parts (no metastatic disease).
- You are eligible to take neratinib for extended adjuvant treatment as listed in China’s prescribing information.
- You do NOT have a medical reason you can’t take neratinib (a contraindication).
- You are not currently in, and will not join, another interventional clinical trial within 4 weeks before starting this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding neratinib to Kadcyla (T-DM1) can help eliminate “molecular residual disease,” meaning tiny traces of cancer left after surgery and standard HER2 treatment. It’s for adults with HER2-positive breast cancer who still test positive after a short course of Kadcyla, with no signs of cancer returning or spreading on scans.
This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
This early-phase trial tests a combination of two targeted drugs, neratinib and ruxolitinib, for people with metastatic triple-negative breast cancer who have already had standard chemotherapy. The goal is to see if the combination is safe and effective.
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.